Acute Pharyngitis Market Report 2026

The acute pharyngitis market size has grown strongly in recent years. It will grow from $2.89 billion in 2025 to $3.13 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to high prevalence of viral and bacterial pharyngitis, limited treatment awareness, increasing healthcare infrastructure, rising outpatient visits, growing pharmaceutical availability.

The acute pharyngitis market size is expected to see strong growth in the next few years. It will grow to $4.25 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to development of novel antivirals and antibiotics, increasing telemedicine adoption, growth of online pharmacy platforms, rising awareness of herbal and alternative remedies, expansion of homecare and specialty care services. Major trends in the forecast period include rising use of antibiotics and antivirals for acute pharyngitis, growing adoption of over-the-counter medications, increasing preference for herbal and alternative remedies, expansion of hospital and homecare treatment options, focus on anti-inflammatory and corticosteroid therapies.

A rise in the prevalence of influenza is expected to drive the growth of the acute pharyngitis market going forward. Influenza results from infection with influenza viruses, which spread through respiratory droplets from coughs, sneezes, or contact with contaminated surfaces. The increasing prevalence of influenza is influenced by factors such as seasonal variations, low vaccination rates, higher human mobility, viral mutations, and weakened immunity in certain populations. Treatment for acute pharyngitis helps influenza patients by reducing throat inflammation and pain, easing discomfort while swallowing, preventing secondary bacterial infections, and supporting overall recovery. When combined with antiviral medications, adequate hydration, and rest, it enhances the body’s ability to combat the influenza virus more effectively. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, as of February 2025, the percentage of clinical lab tests positive for influenza reached 31.6%, up from 29.4% the previous week and 18.6% at the start of the year. Therefore, the rise in influenza prevalence is driving the growth of the acute pharyngitis market.

The high prevalence of respiratory infections is expected to further propel the growth of the acute pharyngitis market in the coming years. Acute pharyngitis, an inflammation of the pharynx commonly caused by viral or bacterial infections, results in sore throat, fever, and difficulty swallowing. The increasing frequency of respiratory infections, particularly among children and adults during seasonal outbreaks, is a key factor contributing to the growing demand for acute pharyngitis diagnosis and treatment. For instance, in May 2025, according to the Centers for Disease Control and Prevention, a US-based public health agency, chronic obstructive pulmonary disease (COPD) was reported as the fifth leading cause of death in the United States in 2023, accounting for 141,733 deaths. In the same year, the age-adjusted prevalence of diagnosed COPD in adults aged 18 years and older was 3.8 percent. Therefore, the high prevalence of respiratory infections is driving the growth of the acute pharyngitis market.

Major companies operating in the acute pharyngitis market are focusing on developing advanced solutions, such as multiplex syndromic point-of-care (POC) testing, to improve diagnostic speed, enhance accuracy, and support pathogen-specific treatment decisions. Multiplex POC testing is a technological approach that detects multiple pathogens from a single sample in a short time, allowing clinicians to distinguish between viral and bacterial infections and reduce unnecessary antibiotic use. For instance, in June 2024, bioMérieux, a France-based medical equipment manufacturer, received FDA Special 510(k) clearance and a CLIA waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini, which identifies common viral causes of sore throat as well as Group A Streptococcus from a single throat or nasopharyngeal swab in approximately 15 minutes. The test operates on the BIOFIRE SPOTFIRE platform, allowing clinicians to select a smaller or larger multiplex respiratory panel based on need and setting. The Mini panel demonstrates strong sensitivity for four respiratory viruses, including rhinovirus and influenza, and for Streptococcus A, enabling clinicians to make rapid, targeted treatment decisions.

Major companies operating in the acute pharyngitis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, F. Hoffmann La Roche AG, Abbott Laboratories, Bayer AG, Eli Lilly and Company, Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Lupin Limited, Alkem Laboratories Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited.

North America was the largest region in the acute pharyngitis market in 2025. The regions covered in the acute pharyngitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute pharyngitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acute pharyngitis market by increasing costs for imported antibiotics, antivirals, and corticosteroids. Segments such as hospital pharmacy and retail pharmacy are most affected, particularly in regions like north america and europe. This has led to higher treatment costs and supply chain delays. However, tariffs have also encouraged local pharmaceutical manufacturing and innovation in alternative remedies, which can enhance market resilience.

The acute pharyngitis market research report is one of a series of new reports that provides acute pharyngitis market statistics, including acute pharyngitis industry global market size, regional shares, competitors with a acute pharyngitis market share, detailed acute pharyngitis market segments, market trends and opportunities, and any further data you may need to thrive in the acute pharyngitis industry. This acute pharyngitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute pharyngitis is the inflammation of the pharynx, the part of the throat located behind the mouth and nasal cavity. This condition causes a sore throat and may be accompanied by symptoms such as fever, headache, and swollen lymph nodes. It can result from various infections, including viral, bacterial, and fungal, with viral infections being the most common.

The main treatments for acute pharyngitis include antibiotics, antivirals, over-the-counter (OTC) medications, corticosteroids and anti-inflammatory drugs, and alternative remedies. Antibiotics are medications that treat bacterial infections by either killing the bacteria or inhibiting their growth. These treatments are distributed through channels such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by end users including hospitals, homecare, specialty centers, and others.

The acute pharyngitis market consists of revenues earned by entities by providing services such as diagnostic testing services, pharmaceutical dispensing services, and preventive and vaccination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute pharyngitis market also includes sales of penicillin, amoxicillin, azithromycin, throat gargles and rinses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.